Shares of Calithera Biosciences Inc. (NASDAQ:CALA) fell 2.1% during trading on Tuesday . The company traded as low as $3.14 and last traded at $3.28, with a volume of 120,352 shares trading hands. The stock had previously closed at $3.35.

A number of equities analysts have issued reports on CALA shares. JMP Securities reiterated a “buy” rating on shares of Calithera Biosciences in a report on Wednesday, June 8th. Zacks Investment Research cut Calithera Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, May 17th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Calithera Biosciences in a report on Thursday, May 12th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $10.38.

The stock’s market capitalization is $61.20 million. The stock has a 50-day moving average price of $3.27 and a 200-day moving average price of $4.74.

Calithera Biosciences (NASDAQ:CALA) last posted its earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.03. On average, equities analysts forecast that Calithera Biosciences Inc. will post ($2.16) earnings per share for the current year.

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.